Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Magni

Showing results (41-50 of 235) with videos related to

Pageof 24
Sort By:
Cancer Chemotherapy and Pharmacology|July 2, 2013
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combinationNadia Terranova, Massimiliano Germani, Francesca Del Bene, et al.
Cancer Research|December 11, 2019
A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab ResistanceElena M Tosca, Maurizio Rocchetti, Enrico Pesenti, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 16, 2018
Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugsNicola Melillo, Leon Aarons, Paolo Magni, et al.
Expert Opinion on Drug Discovery|June 28, 2021
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicityElena M Tosca, Roberta Bartolucci, Paolo Magni, et al.
Clinical and Translational Science|February 12, 2020
Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic CancerMaria Garcia-Cremades, Nicola Melillo, Iñaki F Troconiz, et al.
Clinical Pharmacology and Therapeutics|February 10, 2024
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial CarcinomaAlessandro De Carlo, Elena Maria Tosca, Martina Fantozzi, et al.
ADMET & DMPK|March 30, 2022
Building in-house PBPK modelling tools for oral drug administration from literature informationSilvia Grandoni, Nicola Cesari, Giandomenico Brogin, et al.
IEEE/ACM Transactions on Computational Biology and Bioinformatics|July 23, 2011
Summarizing probe intensities of affymetrix GeneChip 3' expression arrays taking into account day-to-day variabilityPaolo Magni, Angela Simeone, Sandra Healy, et al.
American Journal of Physiology. Endocrinology and Metabolism|February 8, 2002
Minimal model S(I)=0 problem in NIDDM subjects: nonzero Bayesian estimates with credible confidence intervalsGianluigi Pillonetto, Giovanni Sparacino, Paolo Magni, et al.
Peptides|December 25, 2007
Cholinergic regulation of neuropeptide Y synthesis and release in human neuroblastoma cellsElena Dozio, Massimiliano Ruscica, Daniel Feltrin, et al.
Pageof 24

Showing results (41-50 of 235) with videos related to

Sort By:
Pageof 24
Cancer Chemotherapy and Pharmacology|July 2, 2013
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combinationNadia Terranova, Massimiliano Germani, Francesca Del Bene, et al.
Cancer Research|December 11, 2019
A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab ResistanceElena M Tosca, Maurizio Rocchetti, Enrico Pesenti, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 16, 2018
Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugsNicola Melillo, Leon Aarons, Paolo Magni, et al.
Expert Opinion on Drug Discovery|June 28, 2021
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicityElena M Tosca, Roberta Bartolucci, Paolo Magni, et al.
Clinical and Translational Science|February 12, 2020
Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic CancerMaria Garcia-Cremades, Nicola Melillo, Iñaki F Troconiz, et al.
Clinical Pharmacology and Therapeutics|February 10, 2024
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial CarcinomaAlessandro De Carlo, Elena Maria Tosca, Martina Fantozzi, et al.
ADMET & DMPK|March 30, 2022
Building in-house PBPK modelling tools for oral drug administration from literature informationSilvia Grandoni, Nicola Cesari, Giandomenico Brogin, et al.
IEEE/ACM Transactions on Computational Biology and Bioinformatics|July 23, 2011
Summarizing probe intensities of affymetrix GeneChip 3' expression arrays taking into account day-to-day variabilityPaolo Magni, Angela Simeone, Sandra Healy, et al.
American Journal of Physiology. Endocrinology and Metabolism|February 8, 2002
Minimal model S(I)=0 problem in NIDDM subjects: nonzero Bayesian estimates with credible confidence intervalsGianluigi Pillonetto, Giovanni Sparacino, Paolo Magni, et al.
Peptides|December 25, 2007
Cholinergic regulation of neuropeptide Y synthesis and release in human neuroblastoma cellsElena Dozio, Massimiliano Ruscica, Daniel Feltrin, et al.
Pageof 24